cm-082
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started May 1, 2013 (NCT01863485)
Timeline
Indications
Mechanism of action
PDGFRB inhibitor
KDR inhibitor
- Stem cell growth factor receptorINHIBITOR
KIT inhibitor
FLT3 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545427 ↗
Also known as
- cm082
- cm-082
- cm-082
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03095040 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2017 | AnewPharma, Peking University |
| NCT02577458 | Phase 1 | Sep 1, 2015 | AnewPharma, Peking University |
| NCT02452385 | Phase 1 | Mar 1, 2015 | AnewPharma, Sichuan University |
| NCT01863485 | Phase 1 | May 1, 2013 | AnewPharma, Chinese Academy of Medical Sciences |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AnewPharma | For profit | 4 | 4 | 2 | 2013 |
| Peking University | Academic/Hospital | 2 | 0 | 2 | 2015 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Sichuan University | Academic/Hospital | 1 | 0 | 1 | 2015 |
4 organizations
Page 1 / 1